KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.

Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C Minnema, Leyla Shune, Iris Isufi, Simon J Harrison, Urvi A Shah, Jordan M Schecter, Martin Vogel, Nikoletta Lendvai, Katharine S Gries, Eva G Katz, Ana Slaughter, Carolina Lonardi, Jane Gilbert, Quanlin Li, William Deraedt, Octavio Costa Filho, Nitin Patel, Erika Florendo, Lionel Karlin, Katja Weisel

Lancet Haematol 12(1) e45-e56

PMID39756844
PMCIDPMC12321245
DOI10.1016/S2352-3026(24)00320-X
发表日期2025-01-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes. METHODS: In the ongoing, phase 3, open-label CARTITUDE-4 study, patients were recruited from 81 sites in the USA, Europe, Asia, and Australia, and were randomly assigned 1:1 to cilta-cel (target, 0·75 × 106 CAR-T cells/kg) or standard of care (daratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone). Eligible patients had relapsed, lenalidomide-refractory multiple myeloma, received one to three previous treatment lines including a proteasome inhibitor and an immunomodulatory drug, and had an ECOG performance status of 0 or 1. Secondary endpoints reported here include time to sustained worsening of symptoms (Multiple Myeloma Symptom and Impact Questionnaire [MySIm-Q]; a key secondary endpoint) and change in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire Core C30 (intention-to-treat population) and EuroQol 5-Dimension 5-Level (EQ-5D-5L; intention-to-treat population). This study is registered with ClinicalTrials.gov number NCT04181827 and is ongoing. FINDINGS: Patients were enrolled from July 10, 2020, to Nov 17, 2021, and 419 of 516 screened patients were randomly assigned (cilta-cel, n=208; standard of care, n=211; median follow-up, 15·9 months [IQR 12·4 to 17·8]); median age was 61 years. 191 (92%) of 208 patients in the cilta-cel group and 190 (91%) of 209 evaluable patients in the standard- of-care group completed baseline assessments. MySIm-Q compliance post-baseline was 70 to 81% (cilta-cel) and 79 to 89% (standard of care). MySIm-Q median time to sustained symptom worsening with cilta-cel versus standard of care was 23·7 versus 18·9 months (HR 0·42; 95% CI 0·26 to 0·68). 12-month mean changes for EORTC global health status (GHS) were +10·1 (95% CI 7·0 to 13·1) and -1·5 (95% CI -5·3 to 2·3) points and were +8·0 (95% CI 5·2 to 10·7) and +1·4 (95% CI -1·9 to 4·7) points for EQ-5D-5L visual analogue scale (VAS). Rates of clinically meaningful improvements in GHS and VAS were higher with cilta-cel than with standard of care. INTERPRETATION: Health-related QoL improvements and delayed symptom worsening support cilta-cel's clinical efficacy in lenalidomide-refractory disease. FUNDING: Janssen Research & Development, Legend Biotech USA.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1:. Multiple Myeloma Symptom and Impact Questionnaire assessments (A) Compliance rate over time. *Compliance rates were similar across MySIm-Q, EORTC QLQ-C30, and EQ-5D-5L assessments. †In cilta-cel group. ‡Baseline patient-reported outcome assessment timepoint. §In the SOC group. ¶Approximate study day 85. ‖Cycle 4 in patients receiving DPd. Cycle 5 in patients receiving PVd. (B) Time to sustained worsening in total symptom score (C) Least-squares mean change (95% CI) from baseline over time on the total symptoms subscale. (D) Least-squares mean change (95% CI) from baseline over time on the total impact subscale. (E) Proportion of patients with clinically meaningful changes from baseline (≥0·32-point difference) in symptom scores at month 12. C4/5=SOC group DPd cycle 4 or PVd cycle 5. Cilta-cel=ciltacabtagene autoleucel. DPd=daratumumab, pomalidomide, and dexamethasone. P=post-infusion day 28 in the cilta-cel group. PVd=pomalidomide, bortezomib, and dexamethasone. SOC=standard of care.

B

Time to sustained worsening in total symptom score

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2:. EORTC QLQ-C30 assessments (A) Least-squares mean change (95% CI) from baseline over time in global health status. (B) Least-squares mean change (95% CI) from baseline over time in emotional functioning. (C) Least-squares mean change (95% CI) from baseline over time in pain. (D) Least-squares mean change (95% CI) from baseline over time in fatigue. (E) Proportion of patients with clinically meaningful changes from baseline (≥10-point difference) in EORTC QLQ-C30 global health status, physical functioning, fatigue, and pain scores at month 12. C4/5=standard-of-care group DPd cycle 4 or PVd cycle 5. *Percentages do not sum to 100% due to rounding. Cilta-cel=ciltacabtagene autoleucel. DPd=daratumumab, pomalidomide, and dexamethasone. EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core C30. PVd=pomalidomide, bortezomib, and dexamethasone. P=postinfusion day 28 in the cilta-cel group. SOC=standard of care.
非 KM Figure
Figure 3Figure 3:. EuroQol 5-dimension 5-level assessments (A) Least-squares mean change (95% CI) from baseline over time on the visual analogue scale. (B) Proportion of patients with clinically meaningful changes from baseline (≥7-point difference) in visual analogue scale score at month 12. C4/5=SOC group DPd cycle 4 or PVd cycle 5. Cilta-cel=ciltacabtagene autoleucel. DPd=daratumumab, pomalidomide, and dexamethasone. P=postinfusion day 28 in the cilta-cel group. PVd=pomalidomide, bortezomib, and dexamethasone. SOC=standard of care.
非 KM Figure